TY - JOUR
T1 - STI NG-associated vasculopathy develops independently of IRF3 in mice
AU - Warner, James D.
AU - Irizarry-Caro, Ricardo A.
AU - Bennion, Brock G.
AU - Ai, Teresa L.
AU - Smith, Amber M.
AU - Miner, Cathrine A.
AU - Sakai, Tomomi
AU - Gonugunta, Vijay K.
AU - Wu, Jianjun
AU - Platt, Derek J.
AU - Yan, Nan
AU - Miner, Jonathan J.
N1 - Funding Information:
The Miner laboratory is supported by grants from the National Institutes of Health (NIH; K08AR070918) and the Rheumatology Research Foundation. The Yan laboratory is supported by grants from the National Institutes of Health (R01AR067135) and the Burroughs Wellcome Fund. J.D. Warner and R.A. Irizarry-Caro are both supported by NIH T32 training grants (5T32AR007279-39 at Washington University in St. Louis and 5T32AI005284-38 at UT Southwestern Medical Center). The authors declare no competing financial interests.
Publisher Copyright:
© 2017 Warner et al.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Patients with stimulator of interferon genes (STI N G)-associated vasculopathy with onset in infancy (SAVI) develop systemic inflammation characterized by vasculopathy, interstitial lung disease, ulcerative skin lesions, and premature death. Autosomal dominant mutations in STI N G are thought to trigger activation of IRF3 and subsequent up-regulation of interferon (IFN)- stimulated genes (ISGs) in patients with SAVI. We generated heterozygous STI N G N153S knock-in mice as a model of SAVI. These mice spontaneously developed inflammation within the lung, hypercytokinemia, T cell cytopenia, skin ulcerations, and premature death. Cytometry by time-of-flight (CyTO F) analysis revealed that the STI N G N153S mutation caused myeloid cell expansion, T cell cytopenia, and dysregulation of immune cell signaling. Unexpectedly, we observed only mild up-regulation of ISGs in STI N G N153S fibroblasts and splenocytes and STI N G N154S SAVI patient fibroblasts. STI N G N153S mice lacking IRF3 also developed lung disease, myeloid cell expansion, and T cell cytopenia. Thus, the SAVI-associated STI N G N153S mutation triggers IRF3-independent immune cell dysregulation and lung disease in mice.
AB - Patients with stimulator of interferon genes (STI N G)-associated vasculopathy with onset in infancy (SAVI) develop systemic inflammation characterized by vasculopathy, interstitial lung disease, ulcerative skin lesions, and premature death. Autosomal dominant mutations in STI N G are thought to trigger activation of IRF3 and subsequent up-regulation of interferon (IFN)- stimulated genes (ISGs) in patients with SAVI. We generated heterozygous STI N G N153S knock-in mice as a model of SAVI. These mice spontaneously developed inflammation within the lung, hypercytokinemia, T cell cytopenia, skin ulcerations, and premature death. Cytometry by time-of-flight (CyTO F) analysis revealed that the STI N G N153S mutation caused myeloid cell expansion, T cell cytopenia, and dysregulation of immune cell signaling. Unexpectedly, we observed only mild up-regulation of ISGs in STI N G N153S fibroblasts and splenocytes and STI N G N154S SAVI patient fibroblasts. STI N G N153S mice lacking IRF3 also developed lung disease, myeloid cell expansion, and T cell cytopenia. Thus, the SAVI-associated STI N G N153S mutation triggers IRF3-independent immune cell dysregulation and lung disease in mice.
UR - http://www.scopus.com/inward/record.url?scp=85033401987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033401987&partnerID=8YFLogxK
U2 - 10.1084/jem.20171351
DO - 10.1084/jem.20171351
M3 - Article
C2 - 28951494
AN - SCOPUS:85033401987
SN - 0022-1007
VL - 214
SP - 3279
EP - 3292
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 11
ER -